Trials / Completed
CompletedNCT00405119
A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.
A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Subjects Without Esophageal Erosions
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric-acid suppression. Clinical data on AH234844 demonstrates a rapid onset of action, high potency, and prolonged duration of effect. The present study endeavors, in part, to compare lavoltidine to two GERD drugs, NEXIUM and ranitidine.
Detailed description
A three-part study in healthy male volunteers to determine the most effective of four different lavoltidine doses on gastric pH and to compare the most effective dose with NEXIUM (esomeprazole) 40mg for the inhibition of gastric-acid secretion and with ranitidine (300mg/day) for the amount of pharmacodynamic tolerance
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AH23844 (lavoltidine) | |
| DRUG | NEXIUM (esomeprazole) | |
| DRUG | ZANTAC (ranitidine) |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2006-11-29
- Last updated
- 2017-01-19
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00405119. Inclusion in this directory is not an endorsement.